Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A long-acting buprenorphine delivery system.

R B Pontani, A L Misra

    Pharmacology, Biochemistry, and Behavior
    |March 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    This study introduces a novel implantable buprenorphine delivery system for sustained pain management. The cholesterol-glyceryltristearate matrix provides prolonged drug release, demonstrating efficacy for over 12 weeks in preclinical models.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Sulphabenzide in the treatment of intestinal disorders.

    Calcutta medical journal·2010
    Same author

    Interactions of cocaine with barbital, pentobarbital and ethanol.

    Archives internationales de pharmacodynamie et de therapie·1989
    Same author

    Intravenous kinetics and metabolism of [15,16-3H]naltrexonium methiodide in the rat.

    The Journal of pharmacy and pharmacology·1987
    Same author

    Effect of caffeine on cocaine locomotor stimulant activity in rats.

    Pharmacology, biochemistry, and behavior·1986
    Same author

    Potentiation of morphine analgesia by caffeine.

    British journal of pharmacology·1985
    Same author

    Disposition in the rat of buprenorphine administered parenterally and as a subcutaneous implant.

    Xenobiotica; the fate of foreign compounds in biological systems·1985

    Area of Science:

    • Pharmacology
    • Biomaterials Science
    • Drug Delivery Systems

    Background:

    • Developing long-acting drug delivery systems is crucial for improving patient compliance and therapeutic outcomes.
    • Buprenorphine is an effective analgesic with a potential for abuse, necessitating controlled-release formulations.
    • Existing delivery methods often lack the desired duration of action or biocompatibility.

    Purpose of the Study:

    • To describe a novel subcutaneously implantable buprenorphine delivery system.
    • To evaluate the prolonged release characteristics and in vivo efficacy of the buprenorphine implant.
    • To assess the biocompatibility and safety profile of the implantable device.

    Main Methods:

    • Fabrication of cylindrical buprenorphine implants using a cholesterol-glyceryltristearate matrix.

    Related Experiment Videos

  • In vivo evaluation in rats, assessing the blockade of morphine-induced antinociception.
  • In vitro drug release studies over 12 weeks post-implantation.

    • Main Results:

    • The buprenorphine implant effectively blocked morphine's antinociceptive effects for over 12 weeks.
    • Cumulative drug release at 12 weeks was 43.1%, with release kinetics approximating first-order.
    • The implants exhibited excellent biocompatibility, with no observed toxicity or adverse tissue reactions.

    Conclusions:

    • The cholesterol-glyceryltristearate matrix enables a simple, biocompatible, and effective prolonged-release buprenorphine delivery system.
    • The implant demonstrates potential for extended therapeutic use with minimal side effects.
    • This technology offers a promising alternative for sustained buprenorphine administration.